<DOC>
	<DOCNO>NCT01950416</DOCNO>
	<brief_summary>This two-center , prospective , randomize , single-blind , investigator initiate , pharmacodynamic study parallel design , carry 2 PCI-capable cardiology center ( Patras University Hospital Konstantopoulio General Hospital Athens ) . Patients ST elevation myocardial infarction , undergone fibrinolysis previous 3 48 hour , present high residual PR ( define PRU ≥208 ) admission , pre coronary angiography , randomize write informed consent , 1:1 ratio either : Ticagrelor 180mg loading dose ( LD ) , follow 90mg x2 maintenance dose ( MD ) start 12±6 hour post LD , discharge . Or Clopidogrel 600mg load dose ( LD ) , follow 150mg daily maintenance dose ( MD ) start 12±6 hour post LD , discharge . Platelet reactivity assessment perform randomization ( Hour 0 ) 2 , 24 hour randomization , well pre-discharge , use VerifyNow assay , platelet reactivity unit ( PRU ) . Documentation major adverse cardiac event ( death , myocardial infarction , stroke , ischemia drive revascularization procedure PCI CABG ) bleeding ( accord BARC criterion ) perform patient 's discharge .</brief_summary>
	<brief_title>Ticagrelor v High Dose Clopidogrel Patients With ST Elevation Myocardial Infarction Post Fibrinolysis</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Age 1885 year old 2 . Patients STEMI , undergone fibrinolytic therapy previous 3 48 hour 3 . Presenting HPR ( ≥208 PRU ) post 300mg clopidogrel load dose ( assessment immediately coronary angiography ) 4 . Informed consent obtain write Pregnancy Breastfeeding Inability give inform consent Cardiogenic shock Major periprocedural complication ( death , stent thrombosis , vessel perforation , arrhythmia require cardioversion , temporary pacemaker insertion intravenous antiarrhythmic agent , respiratory failure require intubation , vascular injury ( arteriovenous shunt , retroperitoneal bleed ) , major bleeding ( need bood transfusion drop haemoglobin postPCI ≥ 5 gr/ dl intracranial bleeding ) Known hypersensitivity ticagrelor clopidogrel History gastrointestinal bleeding , genitourinary bleeding site abnormal bleeding within previous 3 month . Other bleed diathesis , consider investigator high risk bleed Any previous history stroke , intracranial hemorrhage disease ( neoplasm , arteriovenous malformation , aneurysm ) . Thombocytopenia ( &lt; 100.000 / μL ) randomization Anaemia ( Hct &lt; 30 % ) randomization Polycytaemia ( Hct &gt; 52 % ) randomization Periprocedural IIb/IIIa inhibitor administration Per o anticoagulant Recent ( &lt; 6 week ) major surgery trauma , include GABG . Subjects receive daily treatment nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitor discontinue duration study . Concomitant oral IV therapy strong CY P3A inhibitor ( ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazana vir , grapefruit juice N1 L/d ) , CYP3A substrates narrow therapeutic index ( cyclosporine , quinidine ) , strong CYP3A inducer ( rifampin /rifampicin , phenytoin , carbamazepine ) . Increased risk bradycardiac event . Dialysis require . Severe uncontrolled chronic obstructive pulmonary disease Known severe hepatic impairement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ST elevation myocardial infarction</keyword>
	<keyword>Fibrinolysis</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Platelet reactivity</keyword>
</DOC>